160 related articles for article (PubMed ID: 36574772)
1. Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies.
Pushparaj P; Nicoletto A; Sheward DJ; Das H; Castro Dopico X; Perez Vidakovics L; Hanke L; Chernyshev M; Narang S; Kim S; Fischbach J; Ekström S; McInerney G; Hällberg BM; Murrell B; Corcoran M; Karlsson Hedestam GB
Immunity; 2023 Jan; 56(1):193-206.e7. PubMed ID: 36574772
[TBL] [Abstract][Full Text] [Related]
2. Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses.
Pushparaj P; Nicoletto A; Dopico XC; Sheward DJ; Kim S; Ekström S; Murrell B; Corcoran M; Karlsson Hedestam GB
Front Virol; 2023 Mar; 3():1128253. PubMed ID: 37041983
[TBL] [Abstract][Full Text] [Related]
3. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity.
Avnir Y; Watson CT; Glanville J; Peterson EC; Tallarico AS; Bennett AS; Qin K; Fu Y; Huang CY; Beigel JH; Breden F; Zhu Q; Marasco WA
Sci Rep; 2016 Feb; 6():20842. PubMed ID: 26880249
[TBL] [Abstract][Full Text] [Related]
4. Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection.
Zhang Y; Yan Q; Luo K; He P; Hou R; Zhao X; Wang Q; Yi H; Liang H; Deng Y; Hu F; Li F; Liu X; Feng Y; Li P; Qu L; Chen Z; Pan-Hammarström Q; Feng L; Niu X; Chen L
J Virol; 2022 Feb; 96(4):e0160021. PubMed ID: 34878902
[TBL] [Abstract][Full Text] [Related]
5. Stereotypic neutralizing V
Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
[TBL] [Abstract][Full Text] [Related]
6. Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants.
Yan Q; Hou R; Huang X; Zhang Y; He P; Zhang Y; Liu B; Wang Q; Rao H; Chen X; Zhao X; Niu X; Zhao J; Xiong X; Chen L
Emerg Microbes Infect; 2022 Dec; 11(1):2749-2761. PubMed ID: 36288106
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.
Scheepers C; Shrestha RK; Lambson BE; Jackson KJ; Wright IA; Naicker D; Goosen M; Berrie L; Ismail A; Garrett N; Abdool Karim Q; Abdool Karim SS; Moore PL; Travers SA; Morris L
J Immunol; 2015 May; 194(9):4371-8. PubMed ID: 25825450
[TBL] [Abstract][Full Text] [Related]
9. Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants.
Lunderberg JM; Dutta S; Collier AY; Lee JS; Hsu YM; Wang Q; Zheng W; Hao S; Zhang H; Feng L; Robson SC; Gao W; Riedel S
Front Immunol; 2022; 13():1032574. PubMed ID: 36389829
[TBL] [Abstract][Full Text] [Related]
10. Structural and genetic basis for development of broadly neutralizing influenza antibodies.
Lingwood D; McTamney PM; Yassine HM; Whittle JR; Guo X; Boyington JC; Wei CJ; Nabel GJ
Nature; 2012 Sep; 489(7417):566-70. PubMed ID: 22932267
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouse
Yang X; Chi H; Wu M; Wang Z; Lang Q; Han Q; Wang X; Liu X; Li Y; Wang X; Huang N; Bi J; Liang H; Gao Y; Zhao Y; Feng N; Yang S; Wang T; Xia X; Ge L
Front Immunol; 2022; 13():992787. PubMed ID: 36211410
[TBL] [Abstract][Full Text] [Related]
12. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
[TBL] [Abstract][Full Text] [Related]
13. Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.
Arons E; Henry K; Haas C; Gould M; Tsintolas J; Mauter J; Zhou H; Burbelo PD; Cohen JI; Kreitman RJ
J Med Virol; 2023 Oct; 95(10):e29179. PubMed ID: 37877800
[TBL] [Abstract][Full Text] [Related]
14. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
15. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
16. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
Front Immunol; 2021; 12():715464. PubMed ID: 34539645
[TBL] [Abstract][Full Text] [Related]
17. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
18. Widespread impact of immunoglobulin V-gene allelic polymorphisms on antibody reactivity.
Yuan M; Feng Z; Lv H; So N; Shen IR; Tan TJC; Teo QW; Ouyang WO; Talmage L; Wilson IA; Wu NC
Cell Rep; 2023 Oct; 42(10):113194. PubMed ID: 37777966
[TBL] [Abstract][Full Text] [Related]
19. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma.
Voss WN; Hou YJ; Johnson NV; Kim JE; Delidakis G; Horton AP; Bartzoka F; Paresi CJ; Tanno Y; Abbasi SA; Pickens W; George K; Boutz DR; Towers DM; McDaniel JR; Billick D; Goike J; Rowe L; Batra D; Pohl J; Lee J; Gangappa S; Sambhara S; Gadush M; Wang N; Person MD; Iverson BL; Gollihar JD; Dye J; Herbert A; Baric RS; McLellan JS; Georgiou G; Lavinder JJ; Ippolito GC
bioRxiv; 2020 Dec; ():. PubMed ID: 33398269
[TBL] [Abstract][Full Text] [Related]
20. Identification of Human Single-Domain Antibodies against SARS-CoV-2.
Wu Y; Li C; Xia S; Tian X; Kong Y; Wang Z; Gu C; Zhang R; Tu C; Xie Y; Yang Z; Lu L; Jiang S; Ying T
Cell Host Microbe; 2020 Jun; 27(6):891-898.e5. PubMed ID: 32413276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
